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Rationale: Although airway inflammation can persist for years after
smoking cessation in patients with chronic obstructive pulmonary
disease (COPD), the mechanisms of persistent inflammation are
largely unknown.
Objectives:We investigatedrelationshipsbetweenbronchial epithelial
remodeling, polymeric immunoglobulin receptor (pIgR) expression,
secretory IgA (SIgA), airway inflammation, and mural remodeling in
COPD.
Methods: Lung tissue specimens and bronchoalveolar lavage were
obtainedfromlifetimenonsmokersandformersmokerswithorwith-
outCOPD.Epithelialstructuralchangeswerequantifiedbymorphomet-
ric analysis. ExpressionofpIgRwasdeterminedby immunostainingand
real-time polymerase chain reaction. Immunohistochemistry was per-
formed for IgA, CD4 and CD8 lymphocytes, and cytomegalovirus and
Epstein-Barr virus antigens. Total IgAandSIgAweremeasuredbyELISA
and IgA transcytosis was studied using cultured human bronchial
epithelial cells.
Measurements andMainResults: Areasofbronchialmucosacoveredby
normal pseudostratified ciliated epithelium were characterized by
pIgRexpressionwithSIgApresentonthemucosal surface. Incontrast,
areas of bronchial epithelial remodeling had reduced pIgR expres-
sion, localized SIgA deficiency, and increased CD41 and CD81 lym-
phocyte infiltration. In small airways (,2 mm), these changes were
associatedwithpresence of herpesvirus antigens, airwaywall remod-
eling, and airflow limitation in patients with COPD. Patients with
COPD had reduced SIgA in bronchoalveolar lavage. Air–liquid inter-
faceepithelial cell cultures revealed that complete epithelial differen-
tiationwas required for normal pIgR expression and IgA transcytosis.
Conclusions: Our findings indicate that epithelial structural abnor-
malities lead to localized SIgA deficiency in COPD airways. Impaired
mucosal immunitymaycontribute topersistentairway inflammation
and progressive airway remodeling in COPD.
Keywords: polymeric immunoglobulin receptor; bronchial epithelium;
cell differentiation; epithelial remodeling; mucosal host defense
In chronic obstructive pulmonary disease (COPD), airway in-
flammation can persist for years, even after cessation of tobacco
smoke exposure (1, 2). Recent studies have shown that struc-
tural and functional disorders of bronchial epithelium also per-
sist in former smokers with COPD (3–5). Therefore, it is
plausible that defective physical and immunobarrier functions
of structurally abnormal bronchial epithelium may be associ-
ated with perpetuation (or progression) of airway inflammation,
which is thought to be a key factor in the pathogenesis of
COPD.
Together with the mucociliary escalator, secretory immuno-
globulin A (SIgA) prevents adherence to or invasion of bron-
chial epithelium by viral or bacterial pathogens and other
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Airway inflammation often persists for a prolonged period
of time after smoking cessation in patients with chronic
obstructive pulmonary disease (COPD), but the reason for
this finding is obscure. Secretory immunoglobulin A (SIgA),
together with mucociliary clearance, prevents adherence to
or invasion of bronchial epithelium by pathogens and other
foreign antigens, acting as a scavenger through so-called
“immune exclusion.” Therefore, impaired mucosal immu-
nity could contribute to chronic or recurrent airway in-
flammation in patients with COPD.
What This Study Adds to the Field
In patients with COPD, bronchial epithelial remodeling is
associated with down-regulation of polymeric Ig receptor
expression and SIgA deficiency on the epithelial surface of
large and small airways. In small airways, SIgA deficiency
colocalizes with herpesvirus antigens and correlates with
CD81 lymphocyte accumulation, airway remodeling, and
airflow limitation. These data support the concept that re-
duced polymeric Ig receptor expression secondary to al-
tered epithelial cell differentiation leads to defective
mucosal immunity, potentially contributing to a pathologic
cycle of chronic airway inflammation and remodeling in
COPD.
foreign antigens, acting as a scavenger through so-called “im-
mune exclusion” (6, 7). Structurally, SIgA consists of a secretory
component (SC) and two or more IgA monomers joined with J
chain. IgA monomers and J chains are synthesized and assem-
bled to polymeric IgA (pIgA) by subepithelial or glandular in-
terstitial plasma cells, whereas SC is derived from the pIgA
receptor (pIgR) expressed in ciliated cells of bronchial epi-
thelium and the serous cells of submucosal glands. Selective
binding of J chain with pIgR and subsequent transcytosis of
pIgR–IgA complexes across bronchial and glandular epithelium
is the basic mechanism of SIgA secretion (7–9). SIgA then
accumulates in the periciliary fluid that forms a thin continuous
film on epithelial surface. In large airways, surface SIgA may be
derived from local transcytosis across bronchial epithelium and
secretion from submucosal glands. Because small airways lack
submucosal glands, only the former mechanism can account for
surface SIgA delivery in distal bronchi (6, 7).
In COPD, reduced SC expression in bronchial epithelium has
been associated with neutrophil infiltration and airflow limita-
tion (6, 10). Whether a generalized SIgA deficiency exists in
the lungs of patients with COPD is unknown, because pulmo-
nary SIgA levels have not been investigated in this clinical set-
ting. However, a previous study reported reduced IgA levels in
bronchoalveolar lavage (BAL) fluid from patients with chronic
bronchitis (11). Consistent with the notion of impaired host de-
fense in COPD, bacteria and viruses, including Epstein-Barr
virus (EBV), are often found in airways of patients with COPD
(12–14). We postulated that bronchial epithelial remodeling,
which is common in COPD, leads to abnormalities in SIgA
trafficking to the airway that impair local host defenses, increase
exposure to inhaled antigens, and perpetuate airway inflamma-
tion. Together, our results shed light on the cause and conse-
quences of chronic airway inflammation in former smokers with
COPD. Some of the findings of the present study have been
published in abstract form (15, 16).
METHODS
Clinical Material
Lung tissue specimens containing large (segmental and subsegmental)
or small (diameter ,2 mm) airways were collected from lifetime non-
smokers without known lung or cardiovascular disease (never smokers)
and former smokers with or without COPD. Tissue specimens from 30
lifetime nonsmokers and 6 former smokers without COPD were
obtained from donor lungs that were not used for lung transplantation.
Tissue specimens from 10 former smokers without COPD and 22
patients with mild-to-moderate COPD (Global Initiative for Chronic
Obstructive Lung Disease [GOLD] stage I–II) (17) were obtained from
lungs resected for solitary tumors, whereas tissue specimens from 32
patients with severe-to-very-severe COPD (GOLD stage III–IV) (17)
were obtained from the explanted lungs of transplant recipients. All
individuals included in this study had abstained from smoking for more
than 1 year (Table 1). The study was approved by the Institutional
Review Board of Vanderbilt University, Nashville, Tennessee.
Airway Histology and Immunohistochemistry
Paraffin sections (5 mm) were stained with hematoxylin and eosin for
routine histologic evaluation, periodic acid–Schiff reaction for detec-
tion of mucin, or Masson trichrome for analysis of fibrous remodeling.
Double immunofluorescence microscopy was performed using five dif-
ferent pairs of primary antibodies: (1) IgA and SC/pIgR, (2) IgA and
CD138, (3) IgA and CD8, (4) IgA and cytomegalovirus (CMV) late
antigen, (5) or IgA and EBV-latent membrane protein. The murine
monoclonal anti-SC/pIgR antibody used (clone SC-05; Abcam Inc.,
Cambridge, MA) demonstrated consistent staining on the basolateral
surfaces, but not the apical surfaces of ciliated epithelial cells, suggest-
ing that the antibody binds only pIgR but not the SC of SIgA mole-
cules. Primary antibodies used were a rabbit polyclonal for IgA; CD138
(DakoCytomation, Carpinteria, CA); CMV (Millipore Corporation,
Billerica, MA); EBV; and CD4 or CD8 (Abcam, Cambridge, MA).
The specificity of immunohistochemistry (IHC) was verified using an
antibody isotype control replacing the primary antiserum with an iden-
tical concentration of nonimmunized mouse or rabbit serum (Invitro-
gen Corporation, Camarillo, CA).
Morphometry
In large airway tissue samples, the percentage of bronchial mucosa cov-
ered by normal-appearing pseudostratified ciliated epithelium and its
various pathologic states (Table 2) (18) was determined for each tissue
sample by recording the length of basement membrane subjacent to
each morphologic category. For each histologically defined region of
bronchial epithelium, the numbers of intraepithelial and subepithelial
CD41 and CD81 lymphocytes were calculated per 1 mm2 of epithelium
or lamina propria (the space between the reticular basement mem-
brane and smooth muscle layer).
In small airways, the amount of IgA on the epithelial surface was
quantified by measurement of IgA-specific fluorescent signal. Data
are presented as actual pixel value. Airways with actual pixel value less
than 30 were considered IgA-deficient.
TABLE 1. CLINICAL CHARACTERISTICS OF STUDY PARTICIPANTS*
Never Smokers Former Smokers without COPD†
Patients with COPD Ranged by GOLD Criteria (17)
COPD I COPD II COPD III COPD IV
Number of study participants
VUMC 3 10 8 14 10 22
UCSF 27 6 0 0 0 0
FEV1,% of predicted N/A 100.2 6 11.3 86.8 6 5
‡ 63.9 6 7.6‡ 37.1 6 6.5‡ 21.1 6 4.4‡
FEV1 / FVC, % of FVC N/A 0.89 6 0.33 0.65 6 0.04
‡ 0.54 6 0.08‡ 0.41 6 0.07‡ 0.32 6 0.09‡
Age, yr 49.3 6 16.6 56.4 6 15.1 64.1 6 5.5x 68.7 6 8‡x 62.2 6 7.4x 55.2 6 5.9
Sex
Male 13 9 4 8 6 10
Female 17 7 4 6 4 12
Smoking history
Pack-year N/A 35.6 6 20.6 48.6 6 13.6 61.3 6 25.3‡ 54.7 6 19.3‡ 45.3 6 16.2
Smoke free, if quit, yr N/A 10.1 6 7.6 5.3 6 2.8‡ 9.6 6 5.7 7.7 6 6.2 5.3 6 4.5‡
Definition of abbreviations: GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease; UCSF ¼ University of California, San Francisco; VUMC ¼ Vanderbilt
University Medical Center.
* SD is indicated for each parameter.
y Spirometry data were available for 10 study participants who underwent lung resection for solitary tumors.
z P , 0.05 compared with former smokers without COPD.
x P , 0.05 compared with never smokers.
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On tissue sections immunostained with anti-IgA antibodies, small
airway remodeling was analyzed by morphometry. Airway wall remod-
eling was evaluated by measurement of subepithelial connective tissue
volume density (VVsub) as the difference in the area, delimited by the
basement membrane and the outer edge of the airway adventitia, di-
vided by the length of subepithelial basement membrane according to
the recommendations of Hogg and colleagues (19).
On tissue sections double immunostained for IgA and CD8, the
number of CD81 lymphocytes within the epithelium (intraepithelial)
or localized between the basement membrane and the outer edge of
adventitia (subepithelial) were enumerated and normalized to the
length of basement membrane. Average VVsub and CD8
1 cell counts
were calculated for each study participant. These parameters were also
calculated separately for IgA-positive and IgA-deficient airways in
each study subject. For further technical details regarding morphomet-
ric analyses, refer to the online supplement. All morphometric meas-
urements were made using Image-Pro Express software (Media
Cybernetics, Bethesda, MD).
Laser Capture Microdissection
Lung parenchymal tissue specimens from five lifelong nonsmokers with-
out COPD and five former smokers with very severe COPD (GOLD
stage IV) were immediately snap frozen with liquid nitrogen and then
kept in 2808C. Three serial sections were made from each tissue block
and bronchial epithelial cells from small airways from all three sections
were harvested by laser capture microdissection (Veritac LCM; Arc-
turus Bioscience, San Francisco, CA).
Determination of IgA and SIgA in BAL Fluid
BAL fluid was obtained from 9 lifelong nonsmokers, 8 former smokers
without COPD, and 10 former smokers with COPD (see Table E1).
Bronchoscopy with collection of BAL was approved by the Institu-
tional Review Board of National Jewish Health, Denver, Colorado.
BAL fluid was recovered using 60-ml saline lavage with the broncho-
scope wedged in the anterior segment of the right upper lobe. Col-
lected fluids were centrifuged at 1,500 3 g for 10 minutes at 48C and
the supernatant was immediately frozen at 2808C. Total IgA and SIgA
concentrations were measured using specific ELISAs.
Air–Liquid Interface Cultures
Primary human bronchial epithelial cells (HBECs) were obtained from
three lifelong nonsmokers and were cultured as previously described
(20). Culture medium with or without retinoic acid (RA) was used to
promote pseudostratified mucociliary or stratified squamous differen-
tiation, respectively (21). The day of confluence was designated as Day
0 and at Day 28 human plasma IgA enriched with the dimeric form (1:1
ratio of monomeric and dimeric; Athens Research and Technology,
Athens, GA) was added to the basolateral media. Twenty-four hours
later, apical washings were collected and replicate wells were harvested
for histology and pIgR gene and protein analyses. Goat polyclonal anti-
SC/pIgR antibody (R&D Systems, Minneapolis, MN) was used for
IHC and Western blotting. Total IgA and SIgA concentrations in api-
cal washings were measured using specific ELISAs.
Real-time Polymerase Chain Reaction
Total RNA frommicrodissected bronchial epithelial cells was extracted
using theRNAqueous-MicroKit (Applied Biosystems/Ambion, Austin,
TX), according to the manufacturer’s protocol. Total RNA from air-
liquid interface (ALI) cultured cells was isolated using the RNeasy
Mini kit (Qiagen, Valencia, CA), according to the manufacturer’s
specifications. Primer sequences were as follows: PIGR (Forward
59-CTCTCTGGAGGACCACCGT-39, Reverse 59-CAGCCGTGAC-
ATTCCCTG-39), HPRT (Forward 59-TGCTCGAGATGTGATGAA-
GGAG- 39, Reverse 59-TGATGTAATCCAGCAGGTCAGC-39).
Statistical Analyses
Differences among groups were assessed using Kruskal-Wallis rank
analysis of variance with post hoc Dunn multiple comparisons tests.
Differences between pairs were assessed using a Student t test. Corre-
lations were assessed using a Spearman test and frequencies of viral
infections were compared using a chi-square test. Results are presented
as means 6 standard error of the mean (SEM). P values less than 0.05
were considered significant.
RESULTS
SIgA Deficiency in Large Airways
To analyze bronchial epithelium remodeling in this study, we
used a previously published classification scheme based on char-
acteristics of epithelial cell differentiation that was devised to
capture the entire spectrum of pathologic changes of the bron-
chial epithelium found in individuals with COPD (Table 2) (18).
In lifelong nonsmokers and former smokers without COPD,
epithelium with normal pseudostratified ciliated appearance
predominated (Figures 1A and 1F). In early stage COPD
TABLE 2. HISTOLOGIC CHARACTERISTICS OF BRONCHIAL EPITHELIAL REMODELING
Structural Pattern Histologic Characteristics
I. Normal-appearing pseudostratified ciliated 1. Pseudostratified structure
2. Ratio of goblet cells to ciliated cells z1:8–20
3. Complete differentiation of goblet and ciliated cells
II. Deviated cell differentiation (goblet cell hyperplasia) 1. Pseudostratified structure
2. Predomination of goblet cells among differentiated cells
3. Mild-to-moderate damage to ciliated cells
4. Variable basal cell hyperplasia
IIIa. Incomplete cell differentiation (pseudostratified variant) 1. Pseudostratified structure
2. Surface columnar cells do not show any specific features of ciliated or goblet cells
3. Severe damage to surface columnar cells
4. Cilia absent
5. Variable basal cell hyperplasia
IIIb. Incomplete cell differentiation (stratified variant or
immature squamous metaplasia)
1. Stratified structure
2. Surface cells cuboidal-shaped, do not contact basement membrane, and do not
show any features of either ciliated or goblet cells
3. Severe damage to surface cells
4. Cilia absent
5. Excessive basal cell hyperplasia
IV. Altered cell differentiation (complete squamous metaplasia) 1. Stratified structure
2. Surface cells are flattened
3. Cilia absent
4. Predomination of polygonal cells with multiple cell-to-cell bridges among intermediate cells
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(GOLD stage I–II), 35.3 6 6.4% of the mucosal surface was
covered by epithelium with goblet cell hyperplasia and 10.5 6
3.7% by epithelium with structural patterns of incomplete or
altered cell differentiation. In advanced COPD (GOLD stage
III–IV), most epithelium exhibited abnormal structure. Goblet
cell hyperplasia covered 49.4 6 7.1% of the mucosal surface
and epithelium with incomplete or altered cell differentiation
covered 32.66 6.6% of the mucosal surface (Figures 1B and 1F).
Double immunofluorescence stains demonstrated basolateral
localization of pIgR and apical surface staining for IgA only in
Figure 1. Structural remodel-
ing of large airway epithelium
in chronic obstructive pulmo-
nary disease (COPD) (18).
Rows I and II: (A) Pseudostrati-
fied ciliated bronchial epithe-
lium with normal ratio of
basal, ciliated, and goblet cells.
(B) Pseudostratified bronchial
epithelium with deviated cell
differentiation (goblet cell hy-
perplasia) showing predomi-
nation of goblet cells among
scattered ciliated cells. (C)
Pseudostratified bronchial epi-
thelium with incomplete cell
differentiation; surface cells
have columnar shape but do
not show morphologic fea-
tures of ciliated or goblet cells.
(D) Stratified bronchial epithe-
lium with incomplete cell
differentiation (immature squa-
mous metaplasia); surface cells
have cuboid shape and do not
contact basement membrane.
(E) Bronchial epithelium with
altered cell differentiation (com-
plete squamous metaplasia).
Row III: Abundant polymeric
immunoglobulin receptor (pIgR)
(red) is present within normal-
appearing pseudostratified epi-
thelium (A), but is reduced in
goblet cell hyperplasia (B) and
absent in epithelia with incom-
plete and altered cell differen-
tiation (C–E). Reduced pIgR
expression in bronchial epithe-
lium correlates with significant
reduction in the amount of
IgA (green) on the epithelial
surface (A–E). Row I, hematox-
ylin and eosin–stained paraffin
sections (original magnifica-
tion 3300); row II, electron
micrographs (original magnifi-
cation33,000); row III, double
immunofluorescence with anti-
pIgR (red) and anti-IgA (green)
antibodies, confocal micro-
scope images (original magnifi-
cation 3400). (F) Distribution
of epithelial types shown in A–E lining bronchial mucosal surfaces from lifelong nonsmokers (never smokers), former smokers without COPD, and
patients with mild-moderate (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage I–II) or severe-to-very-severe (GOLD stage III–IV)
COPD. Mean6 SEM is indicated for each epithelial subtype. * P, 0.01 compared with never smokers and former smokers without COPD; ** Epithelial
disorders not detected in never smokers and former smokers without COPD. Increase in intraepithelial and subepithelial CD81 lymphocytes (G) or
CD41 lymphocytes (H) with progression of bronchial epithelial structural disorders. Deviated COPD ¼ cell count in areas with deviated epithelial cell
differentiation in patients with COPD; Inc-Alt COPD ¼ cell count in areas with incomplete or altered epithelial cell differentiation in patients with COPD;
Norm-app COPD ¼ cell count in areas with normal-appearing epithelium in patients with COPD; Norm-app NS ¼ cell count for nonsmokers (both
lifelong nonsmokers and former smokers without COPD). Mean 6 SEM is indicated for each structural variant. * P , 0.01 compared with nonsmoker
group.
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bronchial mucosa covered by normal-appearing pseudostratified
ciliated epithelium. In contrast, areas of the bronchial mucosa
covered by structurally altered epithelium had reduced pIgR ex-
pression in epithelial cells and decreased surface IgA (Figure 1,
row III; see Figure E1). Although pIgR-positive ciliated cells
were present in areas of goblet cell hyperplasia, surface IgA
levels were markedly reduced, likely related to the predomi-
nance of goblet cells in these areas where pIgR expression
was minimal or absent. More advanced structural changes of
the bronchial epithelium (incomplete and altered cell differen-
tiation) were characterized by the absence of both pIgR ex-
pression and surface IgA.
Next, we measured the numbers of CD81 and CD41 lym-
phocytes in intraepithelial and subepithelial compartments in
relation to the structure of the overlying epithelium. No differ-
ences in lymphocyte numbers were observed in control subjects
(both lifelong nonsmokers and former smokers without COPD)
and patients with COPD in areas of bronchial mucosa covered
by normal-appearing pseudostratified epithelium (Figures 1G
and 1H). In contrast, both CD81 and CD41 cell numbers were
modestly increased in areas of bronchial mucosa with goblet cell
hyperplasia and markedly increased in areas covered by epithe-
lium with incomplete or altered differentiation (Figures 1G
and 1H). These findings show that epithelial remodeling is
Figure 2. Small airway muco-
sal secretory immunoglobulin
A (SIgA) deficiency. (A) Airway
with normal-appearing res-
piratory epithelium showing
polymeric Ig receptor (pIgR)
expression (red) in epithelial
cells and surface IgA (green).
(B) Focal goblet cell metaplasia
showing pIgR expression (red)
in epithelial cells and surface
SIgA expression (green). (C)
Extensive goblet cell metapla-
sia with profound reduction in
pIgR in remaining ciliated cells
(red) and absence of surface
SIgA (green). (D) Stratified epi-
thelium negative for pIgR and
surface SIgA. Row I, hematox-
ylin and eosin (HE)–stained
sections (original magnifica-
tion 3100); row II, periodic
acid–Schiff (PAS)–stained tis-
sue sections (original mag-
nification 3400); row III,
immunofluorescence with anti-
IgA antibody (green), confocal
microscope images (original
magnification 3100); row IV,
double immunofluorescence
with anti-pIgR (red) and anti-
IgA (green) antibodies, confocal
microscope images (original
magnification3400). (E) Distri-
bution of epithelial types shown
in 2A–2D lining small airway
mucosa according to clinical
status. Mean 6 SEM is indi-
cated for each epithelial sub-
type. * P , 0.01 compared
with lifelong non-smokers
(never smokers); ** Epithelial
disorders not detected in never
smokers and former smokers
without chronic obstructive
pulmonary disease (COPD).
(F ) Progressive reduction of
IgA-specific fluorescent signal
on epithelial surfaces of small
airways in lifelong non-smokers
(never smokers), former smok-
ers without COPD, and patients with COPD. Mean6 SEM is indicated for each clinical group. * P, 0.01 compared with never smokers. (G) Correlation
between small airway surface SIgA (estimated by IgA-specific fluorescent signal on epithelial surface) and airflow estimated by FEV1 parameter in former
smokers and patients with Grade I–II or Grade III–IV COPD. (H) PIGR mRNA expression in airway epithelial cells. Mean 6 SEM is indicated for each
clinical group. * P , 0.01 compared with never smokers. Apv ¼ actual pixel value.
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associated with SIgA deficiency and lymphocyte accumulation
in large airways.
Robust pIgR expression within the serous cells of bronchial
submucosal glands and numerous interstitial IgA-producing
plasma cells (IgA1/CD1381) were observed in normal-
appearing submucosal glands of lifelong nonsmokers or former
smokers without COPD and hyperplastic submucosal glands
seen in patients with COPD (see Figure E2). Because submu-
cosal glands are a major source of SIgA (6, 7), this finding
suggests that deficiency of IgA on the airway surface develops
despite SIgA secretion in adjacent submucosal glands. There-
fore, production of SIgA by submucosal glands seems unable to
compensate for decreased IgA transcytosis through abnormal
surface epithelia.
SIgA Deficiency in Small Airways
In small airways, varying degrees of goblet cell metaplasia were
demonstrated by periodic acid–Schiff staining (Figures 2A–2C).
In addition, some small airways in patients with COPD showed
a stratified appearance reminiscent of immature squamous
metaplasia seen in large airways (Figure 2D). A progressive
increase in the proportion of airways with abnormal epithelium
was observed among lifelong nonsmokers, former smokers
without COPD, patients with mild-to-moderate COPD (GOLD
stage I–II), and patients with severe-to-very-severe COPD
(GOLD stage III–IV) (Figure 2E). Immunofluorescence mi-
croscopy demonstrated that only normal-appearing epithelium
or epithelium with focal goblet cell metaplasia (involving,25%
of mucosal surface) was positive for pIgR and surface IgA,
whereas both extensive goblet cell metaplasia (involving
$25% of mucosal surface) and stratified transformation were
characterized by absence of pIgR expression and surface IgA
(Figures 2A–2D, see Figure E1). Quantitative analysis demon-
strated an association between decreased surface IgA and the
clinical severity of COPD (Figure 2F). The mean intensity of
the fluorescent signal for surface IgA was slightly reduced in
former smokers without COPD compared with lifelong non-
smokers; however, patients with COPD had a marked reduction
in this parameter compared with either group without COPD,
and patients with the most severe COPD (GOLD stages III–IV)
had the lowest fluorescent signal. In total, there was a striking
direct correlation between surface SIgA and severity of airflow
obstruction as measured by FEV1 (Figure 2G).
To corroborate the reduction of pIgR expression in structur-
ally abnormal small airways, we microdissected epithelial cells
from small airways of lifelong nonsmokers and patients with se-
vere COPD. Quantitative real-time polymerase chain reaction
(RT-PCR) analysis from these samples revealed a significant
down-regulation of PIGR mRNA expression in small airway
epithelium from patients with very severe COPD (Figure 2H).
We investigated for the presence of viral antigens in small air-
way samples to evaluate the consequences of localized mucosal
SIgA deficiency. Based on a recent report of increased herpes-
virus prevalence in COPD (14), we chose to perform double
immunofluorescence studies with primary antibodies against
IgA and EBV or CMV antigens (Figure 3). The proportion of
patients with COPD harboring latent viral antigens in the epi-
thelium was significantly greater than in lifelong nonsmokers
and former smokers without COPD. Interestingly, we found
that more than 90% of virally infected airways were surface
IgA-deficient in patients with COPD (Table 3). Both parame-
ters (percentage of infected patients and percentage of small
airways infected) were higher in patients with severe-to-very-
severe COPD (Table 3). These findings suggest that an im-
paired immunobarrier resulting from localized SIgA deficiency
increases the risk of viral infection, including herpesviruses, in
abnormal airways.
Chronic accumulation of CD81 T lymphocytes in small air-
ways has been considered a major pathogenetic factor in COPD
Figure 3. Association of secretory immunoglobulin A (SIgA) deficiency
and herpesvirus infection in small airways. Images of infected and un-
infected airways are from the same patient with chronic obstructive
pulmonary disease. Double immunofluorescence with primary anti-
IgA (green) and anti–Epstein-Barr virus (EBV) or anti-cytomegalovirus
(CMV) antibodies (red), confocal microscope images (original magni-
fication 3100).
TABLE 3. ANALYSIS OF EBV AND CMV ANTIGENS IN BRONCHIAL EPITHELIUM
Never Smokers Former Smokers without COPD
COPD
GOLD Stage I–II GOLD Stage III–IV
Number of study participants 30 16 22 32
Number of subjects with EBV1 airways (%) 2 (6.7) 2 (12.5) 15 (68.2)* 27 (84.4)*†
EBV1 airways / total airways, % 2.6 3.3 24.4* 40.6*†
IgA1 and EBV1, % 2.6 2.2 2.2 0.6
IgA2 and EBV1, % 0 1.1 22.2*‡ 40*†‡
Number of subjects with CMV1 airways (%) 1 (3.3) 1 (6.3) 8 (36.4)* 18 (56.3)*†
CMV1 airways / total airways, % 1.5 1.1 12.9* 34.4*†
IgA1 and CMV1, % 1 1.1 1.1 0.6
IgA2 and CMV1, % 0.5 0 11.8*‡ 33.8*†‡
Definition of abbreviations: CMV ¼ cytomegalovirus; EBV ¼ Epstein-Barr virus; GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease; IgA ¼
immunoglobulin A.
* P , 0.001 compared with lifelong nonsmokers or former smokers without COPD.
y P , 0.01 compared with GOLD Stage I–II patients with COPD.
z P , 0.001 compared with IgA-positive airways.
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progression, because these cells correlate with disease severity
and persist for years after smoking cessation (22–24). To ana-
lyze the association between CD81 infiltrates and surface SIgA
deficiency, double immunofluorescence studies were performed
with anti-IgA and anti-CD8 antibodies (Figures 4A–4C). In-
creased intraepithelial and submucosal CD81 infiltrates were
observed in surface IgA-deficient airways compared with IgA-
positive airways in all patient groups (Figure 4D). The number
of CD81 cells was also inversely correlated with the amount of
surface IgA (r ¼ 20.842; P , 0.001) (Figure 4E). The increased
weighted averages of CD81 cell infiltrates in patients with
COPD compared with lifelong nonsmokers and former smokers
without COPD was caused by the increased proportion of IgA-
deficient airways in the patients with COPD (Figure 4D).
To determine how SIgA deficiency and chronic airway inflam-
mation could impact airflow obstruction, we evaluated airway
wall remodeling by morphometric analysis in airways with intact
and deficient SIgA (Figures 5A–5C). Increased VVsub (a param-
eter of airway wall thickness) was observed in patients with
COPD compared with lifelong nonsmokers and former smokers
without COPD (Figure 5D). VVsub was increased only in small
airways deficient in surface IgA; the wall thickness of surface
IgA-positive airways was not significantly different among any
of the study groups. As with CD81 T lymphocyte infiltration,
there was a significant inverse correlation between the amount
of surface IgA present and the VVsub of each individual airway
(Figure 5E).
Reduced SIgA in BAL Fluid from Patients with COPD
To investigate whether the reduction in pIgR expression in
COPD airways results in a general deficiency of SIgA, we
obtained BAL samples from a separate group of individuals, in-
cluding 9 lifelong nonsmokers, 8 former smokers without COPD,
and 10 former smokers with COPD. Compared with lifelong
nonsmokers and former smokers without COPD, former smok-
ers with COPD showed significantly reduced SIgA concentration
in BAL fluid without significant differences in total IgA concen-
trations (Figure 6A). These data indicate a generalized SIgA
deficiency in patients with COPD that correlates with airflow
limitation (Figure 6B).
Complete Bronchial Epithelial Cell Differentiation Is Required
for pIgR Expression and IgA Transcytosis In Vitro
Given the association between epithelial remodeling, reduced
pIgR expression, and absence of IgA on mucosal surfaces in air-
ways of patients with COPD, we wanted to test whether com-
plete epithelial differentiation is required for IgA transcytosis
across the bronchial epithelium. Therefore, we used ALI cul-
tures of primary HBECs to model complete and incomplete
epithelial cell differentiation in vitro. In the presence of RA
in basal medium, HBECs fully differentiate to a pseudostratified
ciliated structure. In the absence of RA, HBECs assume a strat-
ified epithelial structure (Figure 7A). Using IHC techniques
with antibodies against SC/pIgR, we detected SC/pIgR expres-
sion in ciliated epithelial cells in RA1 cultures, but no SC/pIgR
expression in RA2 ALI cultures (Figure 7A). In addition, West-
ern blot showed pIgR expression exclusively in RA1 ALI cul-
tures. As demonstrated in Figure 7B, pIgR was detected as
a double band at approximately 100 kD in the cell lysates
obtained from cells grown in presence of RA. These two frac-
tions are nonglycosylated immature (92 kD) and glycosylated
mature (107 kD) pIgR, whereas an additional band at 85 kD is
considered as SC (25). We also performed quantitative RT-
PCR, which showed a significant down-regulation of PIGR
mRNA expression in incompletely differentiated (RA2) HBECs
(Figure 7C).
To assess transcytosis of IgA across bronchial epithelial cells,
IgA was added to the basal media and apical washings were
obtained 24 hours later. Analysis of apical washings demon-
strated successful transepithelial delivery of IgA in RA1 cul-
tures versus minimal delivery in RA2 cultures (Figure 7D).
Separate measurements of total IgA and SIgA using specific
Figure 4. Surface secretory
immunoglobulin A (SIgA) defi-
ciency is associated with in-
creased CD81 T lymphocyte
accumulation in small airways.
(A) Normal-appearing surface
IgA-positive small airway in
lifelong nonsmoker with few
adjacent CD81 cells. (B)
Normal-appearing surface IgA-
positive small airway in a
patient with chronic obstruc-
tive pulmonary disease
(COPD) with slight increase in
intraepithelial and submucosal
CD81 cells. (C) Surface IgA-de-
ficient small airway in a patient
with COPD with a significant
increase in intraepithelial and
submucosal CD81 cells. (A–C)
Double immunofluorescence
with primary anti-IgA (green)
and anti-CD8 (red) antibodies,
confocal microscope images
(original magnification 3100). (D) CD81 cell accumulation predominates in IgA-deficient airways, leading to increased weighted averages. Mean 6
SEM is indicated for IgA-positive and IgA-deficient airways and weighted average in each clinical group. * P , 0.01 compared with lifelong
nonsmokers (never smokers). ** P , 0.01 compared with surface IgA-positive airways from the respective clinical group. (E) Inverse correlation
between small airway surface IgA (estimated by IgA-specific fluorescent signal on epithelial surface) and airway-associated CD81 cells. Apv ¼ actual
pixel value.
Polosukhin, Cates, Lawson, et al.: Secretory IgA Deficiency in COPD 323
ELISAs showed similar concentrations, suggesting that all IgA
detected in apical washings was SIgA. Together, these studies
show a direct relationship between epithelial cell differentia-
tion, pIgR expression, and SIgA delivery to the bronchial epi-
thelial surface, and are consistent with the idea that epithelial
remodeling in COPD is a primary factor in producing localized
SIgA deficiency.
DISCUSSION
Our data indicate that bronchial epithelium remains structurally
and functionally abnormal in patients with COPD for years after
smoking cessation and that the extent of structural changes to the
epithelium in both large and small airways correlates with dis-
ease severity. We found a strong relationship between epithelial
abnormalities, localized deficiency of SIgA on the bronchial mu-
cosal surface, and the presence of CD41 and CD81 lymphocytes.
In addition, we found that mucosal SIgA deficiency is associated
with latent or persistent herpesvirus infection in small conduct-
ing airways, submucosal thickening, fibrotic remodeling of the
airway walls, and severity of airway obstruction. These results
extend previous reports demonstrating associations of airflow
limitation with immune and inflammatory cell infiltration (24,
26, 27) and mural fibrotic remodeling of small airways in COPD
(19, 28) by linking these changes with epithelial remodeling and
deficiency of SIgA on the epithelial surface. In cultured airway
epithelial cells, we found that complete differentiation to a pseu-
dostratified structure was necessary for IgA transcytosis. To-
gether, our findings point to a possible role for epithelial
structural abnormalities and impaired mucosal immunity in per-
sistent airway inflammation and functional decline in former
smokers with COPD.
We showed that SIgA-mediated bronchial mucosal host
defense is closely associated with bronchial epithelial cell
Figure 5. Surface secretory
immunoglobulin A (SIgA) defi-
ciency is associated with mural
remodeling of small airways.
(A) Normal-appearing surface
SIgA-positive small airway in
lifelong nonsmoker showing
a thin, nonfibrotic submucosa.
(B) Normal-appearing surface
SIgA-positive small airway in
a patient with chronic ob-
structive pulmonary disease
(COPD) showing moderate
submucosal fibrosis, but with-
out significantly increased wall
thickness. (C ) Surface SIgA-
deficient small airway in COPD
patient showing marked sub-
mucosal fibrosis and signif-
icant thickening of the airway
wall. Row I, immunofluores-
cence with anti-IgA antibody
(green) (original magnifica-
tion 3100); red lines delineate
airway wall thickness. Row II,
trichrome-stained tissue sections
(original magnification 3100).
(D) Wall thickness (VVsub) pre-
dominates in SIgA-deficient
airways, leading to increased
weighted averages. Mean 6
SEM is indicated for SIgA-
positive and SIgA-deficient air-
ways and weighted average in each clinical group. * P , 0.01 compared with lifelong nonsmokers (never smokers). ** P , 0.01 compared with
surface SIgA-positive airways from the same clinical group. (E) Inverse correlation between small airway surface SIgA (estimated by IgA-specific
fluorescent signal on epithelial surface) and airway wall thickness (VVsub). Apv ¼ actual pixel value.
Figure 6. Determination of immuno-
globulin A (IgA) and secretory IgA (SIgA)
in bronchoalveolar lavage (BAL) fluid. (A)
Concentration of total IgA and SIgA in
BAL fluid from lifelong nonsmokers and
former smokers with or without chronic
obstructive pulmonary disease. Mean 6
SEM is indicated for each clinical group.
* P , 0.05 compared with never smokers.
(B) Correlation between SIgA concentra-
tion in BAL fluid and FEV1. COPD ¼
chronic obstructive pulmonary disease.
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differentiation and that only normal-appearing pseudostratified
ciliated epithelium is able to express pIgR and transport pIgA to
the bronchial mucosal surface. In areas of goblet cell hyperplasia,
we found limited SIgA delivery to the epithelial surface despite
pIgR expression in ciliated cells, suggesting that reduced SIgA
delivery in these areas results from a reduction in the number
of epithelial cells responsible for IgA transport rather than alter-
ations in molecular mechanisms of delivery. More severe epithe-
lial structural disorders with incomplete or altered epithelial cell
differentiation were characterized by a lack of pIgR expression
in epithelial cells and striking SIgA deficiency on the luminal sur-
face. Because only a small portion of the bronchial mucosa in
tissue specimens from patients with severe COPD was covered
by normal differentiated bronchial epithelium, our data suggest
widespread bronchial mucosal SIgA deficiency in these patients.
This concept was further supported by identification of reduced
SIgA in BAL from patients with COPD.
Because the pIgR makes only one passage across epithelial
cells before being cleaved (8), one molecule of pIgR must be
produced by the epithelial cell for every pIgA transported
across the epithelial layer. Therefore, diminution of pIgR ex-
pression results in a proportional reduction in pIgA delivery to
the epithelial surface. In airway and intestinal mucosa, pIgR
expression can be transcriptionally up-regulated by proinflam-
matory cytokines (29–32). Thus, our finding that pIgR is re-
duced in the inflammatory environment of the COPD airway
is paradoxical. Whereas the molecular mechanisms responsible
for down-regulation of pIgR in COPD airways requires further
investigation, we speculate that the reduction in pIgR expres-
sion results from altered transcriptional profiles in epithelial
cells that are not completely differentiated. This idea is sup-
ported by our finding of reduced PIGR mRNA expression in
airway epithelium from patients with COPD and incompletely
differentiated epithelium in vitro. Alternatively, it is possible
that reduction in pIgR results from increased protein degrada-
tion, given the prior report that neutrophil serine proteases can
cleave pIgR (33); however, if this were the case it would be hard
to explain the precise correlation between pIgR expression and
epithelial structure in the same airway.
Although surface SIgA deficiency occurs in both large and
small airways, there are differences in the pathophysiologic
mechanisms at these different anatomic sites. In small airways,
SIgA secretion is possible only by local transcytosis via a pIgR-
mediated mechanism (6). Progressive epithelial remodeling and
the associated reduction in pIgR expression subsequently result
in profound surface SIgA deficiency. However, in large airways,
SIgA may be secreted from serous cells of submucosal glands as
an alternative mechanism to local transcytosis (6). Although
hyperplasia of submucosal glands in COPD might suggest in-
creased SIgA secretion and abundance in large airways, we
demonstrate that SIgA deficiency develops on the mucosal sur-
face in large airways despite the presence of submucosal IgA-
producing plasma cells and pIgR expression in submucosal
glandular cells. Although the cause is not clear from our data,
it is possible that damage to the bronchial cilia apparatus and
decreased mucociliary clearance limit mucosal distribution of
SIgA secreted by submucosal glands. Furthermore, dehydration
of periciliary liquid on the epithelial surface, frequently seen in
patients with COPD (34), may preclude adequate storage and
maintenance of surface SIgA. Interestingly, we found reduced
SIgA, but not total IgA, in BAL fluid from patients with COPD.
Although the reason for this discrepancy is not entirely clear,
this imbalance could be caused by increased passive leakage of
serum IgA into airways in patients with COPD instead of se-
cretion via pIgR-dependent mechanisms.
Recent studies have demonstrated an important role for viral
and bacterial pathogens in COPD exacerbations (12, 35). The
most common viral pathogens implicated are rhinovirus, influ-
enza, parainfluenza, and respiratory syncytial virus (12, 36, 37).
Respiratory syncytial virus and adenovirus have been detected
by RT-PCR in a high percentage of patients with stable
COPD, raising the possibility that latent or low-grade viral in-
fection may have implications in the pathogenesis of COPD (12,
13). In this study, we detected EBV and CMV antigens in bron-
chial epithelial cells almost exclusively in SIgA-deficient small
airways. These herpesviruses were chosen for evaluation be-
cause they can establish long-standing latency in host tissues
(38, 39). In addition, EBV and CMV infections have been
Figure 7. Polymeric immunoglobulin re-
ceptor (pIgR) expression and IgA transcytosis
in air-liquid interface (ALI) cultured human
bronchial epithelial cells (HBECs) grown
with or without retinoic acid (RA). (A) Pseu-
dostratified ciliated structure of bronchial
epithelium and marked secretory compo-
nent (SC)/pIgR expression in culture with
RA added; squamous stratified structure of
bronchial epithelium and absent SC/pIgR
expression in culture grown without RA. Top
row: hematoxylin and eosin (HE)–stained par-
affin sections (original magnification 3400).
Bottom row: immunohistochemistry of par-
affin tissue sections with goat polyclonal
anti–SC-pIgR antibody (original magnifica-
tion 3400). (B) Western blot showing ex-
pression of SC/pIgR in cell cultures with
RA added and no pIgR expression in cells
grown without RA. (C) PIGR mRNA expres-
sion in RA1 and RA2 cultures (normalized
to HPRT). (D) IgA and secretory IgA (SIgA)
concentrations in apical washings of ALI
cultured HBECs grown with or without
RA. * P , 0.001 (compared with RA1 cul-
tures). Mean 6 SEM is indicated for each
concentration.
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previously demonstrated in patients with COPD (14) and idio-
pathic pulmonary fibrosis (40, 41). Because one of the host de-
fense functions of surface SIgA is direct intraepithelial viral
clearance (42–46), reduced pIgR expression and impaired pIgA
transcytosis may be critical factors for persistent herpesvirus
infection of bronchial epithelium in COPD.
CD81 cytotoxic T lymphocytes predominate in the inflam-
matory cell infiltrates of small airways in patients with COPD
(22–24). The mechanisms by which these cells are recruited to
airways in COPD are not fully understood, but one possibility is
the immune response to respiratory viral infection (22). Because
CD81 cells play a substantial role in clearance of respiratory
virus via contact-dependent effector functions (47), chronic col-
onization or recurrent or persistent viral infections may be re-
sponsible for T cell–mediated airway cell and tissue injury in
patients with COPD. Chronic inflammatory responses also seem
to induce subepithelial fibrosis that characterizes small airways
in COPD and that contributes to airflow limitation (19, 28, 48).
The strong correlations between small airway SIgA defi-
ciency, viral infection, increased CD81 T lymphocyte infiltra-
tion, airway wall remodeling, and clinical status demonstrated in
this study suggest that mucosal SIgA deficiency may be an im-
portant pathogenetic factor in the development of progression
of COPD. In addition to malfunction of the mucociliary clear-
ance mechanism secondary to bronchial epithelial remodeling
(49), concomitant surface SIgA deficiency likely contributes
to derangement of mucosal immune host defense in COPD.
We speculate that acquired surface SIgA deficiency increases
the risk of chronic or repeated airway infection and enhances
exposure of the bronchial mucosa to inhaled antigens. The
resulting antigen deluge fuels persistent activation of adaptive
immune responses and local accumulation of immune and in-
flammatory effector cells. In turn, chronic airway inflammation
drives further epithelial remodeling and progressive fibrotic
changes in COPD airways. This pathologic sequence may help
to explain the persistence of airway inflammation and bronchial
epithelial remodeling seen in patients with COPD years after
smoking cessation. Importantly, the pathologic cycle proposed
previously may be susceptible to therapeutic measures designed
to alter the progression of disease by restoring mucosal immu-
nity and therefore curtailing ongoing airway inflammation and
fibrotic remodeling.
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